A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC).
about
Advances and Challenges of Liposome Assisted Drug DeliveryTheranostic Probes for Targeting Tumor Microenvironment: An Overview.Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast CancerTargeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advancesTriple Negative Breast Cancer: Nanosolutions for a Big Challenge.Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics.Cancer drug delivery in the nano era: An overview and perspectives (Review)Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines.Prospect of ultrasound-mediated gene delivery in cardiovascular applications.Dendrimer-based nanocarriers: a versatile platform for drug delivery.Liposomal curcumin and its application in cancer.Natural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive AgentsDistinct solubility and cytotoxicity regimes of paclitaxel-loaded cationic liposomes at low and high drug content revealed by kinetic phase behavior and cancer cell viability studies.Effect of antitumor treatments on triple-negative breast cancer patients: A PRISMA-compliant network meta-analysis of randomized controlled trials.Paclitaxel inhibits breast cancer metastasis via suppression of Aurora kinase-mediated cofilin-1 activity.Nanomaterials as nanocarriers: a critical assessment why these are multi-chore vanquisher in breast cancer treatment.Progress and challenges towards targeted delivery of cancer therapeutics.What Is the Role of Nanotechnology in Diagnosis and Treatment of Metastatic Breast Cancer? Promising Scenarios for the Near FutureCancer Vaccine Immunotherapy with RNA-Loaded Liposomes
P2860
Q26773160-749762D9-E1AE-4CC5-B74B-D7EA63422CE8Q30354655-A833E663-DB86-4E96-8B87-E3F1692C6F04Q30366990-51ED9394-0215-45CB-84AA-D9A04289FE64Q36084852-A24F2F67-8C84-495B-A497-EC60AB04441FQ36157045-9BC2EAB4-B34E-494B-BFD1-AFE9B5787AA4Q37422972-3D12EE89-A482-49A0-B434-88C7F7A9DD7BQ38577297-D56C5F05-DBBD-42BF-A053-2CE3E7AA7650Q38669454-D63BBDCA-43CD-406E-9F95-6296350C327DQ38676164-D386041B-F346-4843-ACE0-FC4A5E72A8CBQ38803772-903BCA09-7220-45B8-8015-F77EC3CA48F5Q38820422-396E2AC5-41D7-4C32-94A3-1B423969258BQ41531940-187EF452-1D88-4A8F-9B7C-F882D54387D7Q42755952-FEC16C2C-3623-47CE-AD1E-E3B4859D8CFFQ45932069-ACAE5460-7D4C-41A5-8A1D-D75735945FE1Q47121796-E8197F23-364F-4D7E-BE91-8BA4EF4AFBC5Q50054196-8FF11EEF-B5B2-4CDB-9B0A-AF7DBF6BAE00Q50072050-00E26B1D-A13A-4D2F-832E-37D93336A422Q52590993-50469D9B-5354-41C1-AE60-FB5A29A2FE52Q59128232-FD85F8F4-8C30-4897-A3D8-A9D2AA4C2BD9Q59133785-519A50BC-F89F-42DD-B62C-1C429AA1EF83
P2860
A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC).
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
A randomized controlled phase ...... negative breast cancer (TNBC).
@en
type
label
A randomized controlled phase ...... negative breast cancer (TNBC).
@en
prefLabel
A randomized controlled phase ...... negative breast cancer (TNBC).
@en
P2093
P2860
P356
P1433
P1476
A randomized controlled phase ...... negative breast cancer (TNBC).
@en
P2093
A V Bakshi
CT4002 study group
J Bonneterre
J M Ferrero
P2860
P304
P356
10.1093/ANNONC/MDU025
P577
2014-04-01T00:00:00Z